Meeting
2022 ASCO Annual Meeting
TWT-203: Phase 1b/2 dose-confirming study of CFI-402257 as a single agent in advanced solid tumors and in combination with fulvestrant in patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 and endocrine therapy.
Authors
Robert Wesolowski
The Ohio State University Comprehensive Cancer Center, Division of Medical Oncology, Columbus, OH
Robert Wesolowski , Mark R. Bray , Glenn C. Michelson , Emily L. Roberts-Thomson , Trisha Denny , David W. Cescon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04521413
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS1123)
DOI
10.1200/JCO.2022.40.16_suppl.TPS1123
Abstract #
TPS1123
Poster Bd #
492a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
First Author: Timothy A. Yap
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.
First Author: Sara M. Tolaney
Poster
2019 ASCO Annual Meeting
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials.
First Author: Claudia Omarini
First Author: Peter A. Fasching